Advertisment
UCB’s phase IIa study results of Bepranemab in early Alzheimer’s Disease selected for late-breaking symposium at 2024 CTAD Meeting
UCB announced that the results of its double-blind TOGETHER (AH0003) Phase IIa study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild Alzheimer’s Disease (AD), have been accepted for presentation in a late-breaking symposium at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting. The CTAD meeting will take place in Madrid, Spain, October 29 – November 1, 2024.
The presentation will highlight primary and key secondary results from the Phase IIa study, including clinical, safety, and imaging endpoints. This acceptance underscores UCB’s commitment to addressing the urgent need for new treatment options for Alzheimer’s disease.
“We are pleased to have our innovative research program recognized by the CTAD committee and look forward to sharing the encouraging results of the TOGETHER study with the scientific community. These new data represent an important step in building a rigorous body of evidence evaluating bepranemab as an investigational treatment option, for people living with early Alzheimer’s disease,” said Alistair Henry, Chief Scientific Officer, UCB.
TOGETHER is a Phase IIa, global, multicenter, participant- and investigator-blind, placebo-controlled, parallel-group study designed to investigate the efficacy, safety and tolerability of bepranemab (two dose levels) – administered intravenously every 4 weeks – versus placebo in participants with prodromal (40% of study population) or mild (60% of study population) Alzheimer’s disease over an 80-week treatment period, followed by a 48-week open-label extension period, and a 16-week safety follow-up period.1
Details of the late-breaking symposium:
- Title: Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild Alzheimer’s disease
- Presenters: Martin Citron, PhD (UCB Pharma); Matthew E Barton, PhD (UCB Pharma); Randall J Bateman, MD (Washington University School of Medicine, St Louis, MO, USA)
- Date/Time: October 31, 5:10pm CET
